ABL Bio (298380.KQ), a South Korean bispecific antibody developer, is entering a phase of technology competitiveness reassessment ahead of key pipeline clinical data presentations, according to analysts. Survival data for the bispecific antibody ABL001, set to be disclosed this month, is expected to mark a critical inflection point for the company's regulatory strategy and corporate valuation.
Kim Min-jung, an analyst at DS Investment & Securities, said in a report on Monday that "final duration of response (DoR), median progression-free survival (mPFS), median overall survival (mOS), and safety data from the COMPANION-002 Phase 2/3 trial of ABL001 (DLL4×VEGF-A) are scheduled to be presented in April."
ABL001 previously recorded an objective response rate (ORR) of 17.1%, comprising a 0.9% complete response rate and a 16.2% partial response rate, confirming superior efficacy compared to the existing FOLFOX regimen. The data release was originally planned for the fourth quarter of last year but was delayed, further heightening the significance of the upcoming results. "The fact that an Orphan Drug Designation (ODD) application was filed at the point when survival data is being confirmed suggests that ABL001 is still considered an asset capable of pursuing a regulatory approval pathway," Kim said. "If commercialization succeeds, it would also carry significant implications for subsequent pipeline expansion and demonstrated commercialization capabilities."
ABL111 (Claudin18.2×4-1BB) is also raising commercialization expectations. The candidate is being developed targeting the first-line gastric cancer treatment market, valued at approximately 4.5 trillion won ($3.3 billion). ABL111 demonstrated competitiveness by recording an ORR of 75% in early-stage trials, and a Phase 2 trial is currently underway. Notably, the company has confirmed through consultations with the U.S. Food and Drug Administration (FDA) that an accelerated approval pathway using ORR as the primary endpoint is feasible. "Full data from the Phase 1b trial is expected to be released in the second half of this year," Kim said. "A registration-enabling Phase 3 trial is expected to begin in the fourth quarter."
ABL Bio is also advancing follow-on pipelines to secure next-generation growth drivers. The four key pillars are: ▲antibody-drug conjugates (ADC), ▲blood-brain barrier (BBB) shuttles, ▲trispecific antibodies, and ▲novel central nervous system (CNS) targets. ADC development is being conducted through Neok Bio, a wholly owned subsidiary, in the form of bispecific antibody ADCs and dual-payload ADCs. The company recently committed an additional $25 million in research and development investment. ABL206 and ABL209 have received Phase 1 IND approvals, with early data expected by 2027.
In the BBB shuttle field, the company is expanding from its existing Grabody-B platform into siRNA shuttles while also developing a trispecific antibody platform utilizing IGF-1R, TfR, and CD98. "Since the JP Morgan Healthcare Conference this year, discussions on BBB shuttle technology licensing have been ongoing with multiple global companies," Kim said.
Although ABL Bio's share price has undergone a correction recently due to a delay in ABL301's entry into Phase 2 trials, the company's technological value and business development potential remain intact, according to analysts. "The technological competitiveness of the Grabody-B platform remains solid, and the possibility of collaboration with global pharmaceutical companies is also being maintained," Kim said.
